Lates News

On September 17th, after hours, Novo Nordisk's stock surged by over 2%. According to media reports, Novo Nordisk has submitted a new drug application to the US Food and Drug Administration (FDA) for review before the end of the year. Novo Nordisk's oral version weight loss drug Wegovy showed similar effectiveness to the injectable version in weight loss trials. In a newly published study, Novo Nordisk's oral semaglutide 25 mg (Wegovy tablets*) achieved a 16.6% weight loss in obese individuals. The oral version of semaglutide 25 mg showed improvements in daily physical activity and cardiovascular risk factors. The safety and tolerability profile of the oral semaglutide version is consistent with the injectable version of Wegovy.